A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access device for treatment of liver metastasis in colorectal cancer patients

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523261-25-00

Enrollment

Registered

2026-02-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Brief summary

Incidence of adverse events

Detailed description

Liver Disease Control Rate

Interventions

DRUGOxaliplatin Accord Healthcare 5 mg/ml concentraat voor oplossing voor infusie

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events	—

Secondary

Measure	Time frame
Liver Disease Control Rate	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 28, 2026